Medtech Leader Erica Rogers Joins Ceribell Board of Directors

Rhea-AI Summary

Ceribell (NASDAQ: CBLL), a medical technology company specializing in neurological diagnostics, has appointed Erica Rogers to its Board of Directors. Rogers brings over 30 years of experience in leading medical device companies, most notably as CEO of Silk Road Medical, where she grew the company from a 25-person startup to a 500-employee public company with $175 million in revenue.

Under Rogers' leadership, Silk Road Medical achieved FDA approval and commercial expansion, ultimately leading to its acquisition by Boston Scientific Corporation. Her appointment comes as Ceribell expands its point-of-care EEG system, which is currently used in over 550 hospitals to improve care for critically ill patients.

Positive

• Appointment of highly experienced medtech executive with proven track record of scaling healthcare companies
• New director has successfully led previous company from startup to $175M revenue and acquisition
• Current market penetration in over 550 hospitals demonstrates strong product adoption
• Strategic addition to board during company's growth phase

Negative

• None.

News Market Reaction – CBLL

-0.49%

1 alert

-0.49% News Effect

On the day this news was published, CBLL declined 0.49%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies

SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell’s Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting.

Ms. Rogers is an accomplished healthcare executive with board experience in both the public and private sectors. She most recently served as Chief Executive Officer of Silk Road Medical, Inc. and has held Board positions with HistoSonics, Axena Health, Sight Sciences, LightForce, and Medicines360. At Silk Road, Rogers led the business from its early stages through FDA approval and broad commercial expansion, which ultimately resulted in acquisition by Boston Scientific Corporation. Under her leadership, the organization grew significantly from a 25-person startup to a 500-employee, publicly-traded company with revenue exceeding $175 million. Emphasizing excellence and culture, she is a seasoned founder and leader with a proven track record of innovation, evident in multiple patents and successfully marketed products.

“We welcome Erica at a pivotal growth phase for Ceribell, as we expand nationwide access to our point-of-care EEG system to help clinicians deliver timely care for critically ill patients,” said Jane Chao, PhD, Co-founder and Chief Executive Officer of Ceribell. “Her experience in scaling healthcare companies and driving adoption of new technologies in clinical practice will be invaluable as we work to establish the Ceribell System as the standard of care.”

“Ceribell is pioneering a new era of timely brain monitoring, positively transforming patient outcomes,” said Erica Rogers. “The impact of its groundbreaking rapid EEG technology has already improved care for hundreds of thousands of critically ill patients in more than 550 hospitals. I look forward to supporting its ongoing efforts to broaden access to this significant advancement in healthcare.”

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other statements that are not statements of historical fact. Forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope,” and other words of similar meaning. These statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. These risks and uncertainties are described under the “Risk Factors” sections of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other reports filed with the U.S. Securities and Exchange Commission (“SEC”). These filings are available on the SEC’s website at https://sec.gov/ and on Ceribell’s website at https://investors.ceribell.com/. Ceribell undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

About CeriBell, Inc. 
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow Ceribell on LinkedIn.

Investor Contacts
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com

Media Contact
Corrie Rose
Press@ceribell.com

FAQ

Who is Erica Rogers and why did Ceribell (CBLL) appoint her to the board?

Erica Rogers is a healthcare executive with 30+ years of experience who previously served as CEO of Silk Road Medical, growing it from a startup to a $175M revenue company. She was appointed to help Ceribell expand its EEG system adoption.

What is Ceribell's (CBLL) current market presence in hospitals?

Ceribell's rapid EEG technology is currently used in more than 550 hospitals, helping improve care for hundreds of thousands of critically ill patients.

What was Erica Rogers' track record at Silk Road Medical?

As CEO of Silk Road Medical, Rogers grew the company from 25 employees to 500, achieved FDA approval, led commercial expansion, and reached $175M in revenue before its acquisition by Boston Scientific.

What is Ceribell's (CBLL) main business focus?

Ceribell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions through their point-of-care EEG system.

What other board experience does Erica Rogers bring to Ceribell (CBLL)?

Rogers has held board positions with HistoSonics, Axena Health, Sight Sciences, LightForce, and Medicines360, bringing extensive public and private sector board experience.